Back to Search
Start Over
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster
- Source :
- GlobeNewswire. February 6, 2024
- Publication Year :
- 2024
-
Abstract
- Results Demonstrate Potential Protective Immunity Against Multiple SARS-CoV-2 Variants ATLANTA, GA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- via https://www.globenewswire.com/Tracker?data=KBXurNQ-niuCQsXr2ELsBJpc9Uey6NVFr7fB_Y85guPNfanoDMErXqRd_BOLExcorlPZ2n62pnNg-MXkwWS19T3-h-4UTwBBNbAhNSu4KIY= - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- GlobeNewswire
- Publication Type :
- News
- Accession number :
- edsgcl.781550222